中华麻醉在线
您当前位置:主页 > 热点专题 > 中国发表SCI论文汇总 >

Int J Neurosci:Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.

2017-09-25 12:22  来源:未知  编辑:高国雷   点击:

Abstract

Monoclonal-antibody has been used for patients with autoimmune disorders for several years, and efficacy and safety were appreciated for these patients. Neuromyelitis optica specturm disorder (NMOSD) has been defined as an autoimmune demyelination disorder of the central nervous system (CNS) with a course of relapse-remission. Treatment of prevention is important for patients with NMOSD because of the increased disability after several attacks. Multiple factors were involved in the pathogenesis of NMOSD. Currently, targeting specific factor was favored in the research into the treatment for NMOSD. Previous studies reported the efficacy and tolerance in NMOSD for drugs such as rituximab, tocilizumab, and eculizumab. The aim of this article is to review the current monoclonal therapies for NMOSD patients, and also future alternative options.

KEYWORDS:

Neuromyelitis optica spectrum disorder; eculizumab; monoclonal antibody; rituximab; tocilizumab


相关推荐
网友评论
请自觉遵守互联网相关的政策法规,严禁发布色情、暴力、反动的言论。
评价:
用户名: 验证码: 点击我更换图片
 
Copyright 中华麻醉在线 All rights reserved
地址:北京市东城区东四西大街42号中华医学会南楼2单元222室麻醉学分会办公室 邮编:100710
联系人:白雪   电话:010-85158614   传真:010-85158753   京ICP备14001125
360网站安全检测平台